Marksans Pharma jumps 12% post USFDA nod for anti-allergy drug

MUMBAI: Shares of Marksans Pharma surged over 12 per cent in early trade today after the company received approval from the USFDA for loratadine liquid filled capsules, used for treatment of allergies, in the American market.

The stock jumped 12.53 per cent to Rs 53.85 on BSE.

At NSE, shares of the company climbed 12.89 per cent to Rs 53.85.

"USFDA has granted approval for an abbreviated new drug application (ANDA) for loratadine liquid filled capsules 10 mg", Marksans Pharma said in a BSE filing.

Loratadine liquid filled capsules are therapeutically equivalent to the reference listed drug Claritin Liqui-Gels Capsules 10 mg of Bayer Healthcare LLC, it said.

Loratadine is an antihistamine that reduces the effects of natural chemical histamine in the body. It is used for treating sneezing, runny nose, watery eyes, hives, skin rash, itching and other allergy symptoms.